|
1
|
Martinez AM, Goulart CO, Ramalho BS,
Oliveira JT and Almeida FM: Neurotrauma and mesenchymal stem cells
treatment: From experimental studies to clinical trials. World J
Stem Cells. 6:179–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Varma AK, Das A, Wallace G IV, Barry J,
Vertegel AA, Ray SK and Banik NL: Spinal cord injury: a review of
current therapy, future treatments, and basic science frontiers.
Neurochem Res. 38:895–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bracken MB: Steroids for acute spinal cord
injury. Cochrane Database Syst Rev. 1:CD0010462012.PubMed/NCBI
|
|
4
|
Vawda R and Fehlings MG: Mesenchymal cells
in the treatment of spinal cord injury: current and future
perspectives. Curr Stem Cell Res Ther. 8:25–38. 2013. View Article : Google Scholar
|
|
5
|
Mothe AJ and Tator CH: Advances in stem
cell therapy for spinal cord injury. J Clin Invest. 122:3824–3834.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Himes BT, Neuhuber B, Coleman C, Kushner
R, Swanger SA, Kopen GC, Wagner J, Shumsky JS and Fischer I:
Recovery of function following grafting of human bone
marrow-derived stromal cells into the injured spinal cord.
Neurorehabil Neural Repair. 20:278–296. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Neuhuber B, Timothy Himes B, Shumsky JS,
Gallo G and Fischer I: Axon growth and recovery of function
supported by human bone marrow stromal cells in the injured spinal
cord exhibit donor variations. Brain Res. 1035:73–85. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abrams MB, Dominguez C, Pernold K, Reger
R, Wiesenfeld-Hallin Z, Olson L and Prockop D: Multipotent
mesenchymal stromal cells attenuate chronic inflammation and
injury-induced sensitivity to mechanical stimuli in experimental
spinal cord injury. Restor Neurol Neurosci. 27:307–321.
2009.PubMed/NCBI
|
|
9
|
Novikova LN, Brohlin M, Kingham PJ,
Novikov LN and Wiberg M: Neuroprotective and growth-promoting
effects of bone marrow stromal cells after cervical spinal cord
injury in adult rats. Cytotherapy. 13:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stolzing A and Scutt A: Effect of reduced
culture temperature on antioxidant defences of mesenchymal stem
cells. Free Radic Biol Med. 41:326–338. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hoffmann J, Glassford AJ, Doyle TC,
Robbins RC, Schrepfer S and Pelletier MP: Angiogenic effects
despite limited cell survival of bone marrow-derived mesenchymal
stem cells under ischemia. Thorac Cardiovasc Surg. 58:136–142.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yi T and Song SU: Immunomodulatory
properties of mesenchymal stem cells and their therapeutic
applications. Arch Pharm Res. 35:213–221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Galipeau J: The mesenchymal stromal cells
dilemma - does a negative phase III trial of random donor
mesenchymal stromal cells in steroid-resistant graft-versus-host
disease represent a death knell or a bump in the road? Cytotherapy.
15:2–8. 2013. View Article : Google Scholar
|
|
14
|
Cencioni C, Capogrossi MC and Napolitano
M: The SDF-1/CXCR4 axis in stem cell preconditioning. Cardiovasc
Res. 94:400–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu
H, Che Y, Ou L, Liu L and Kong D: SDF-1/CXCR4 axis modulates bone
marrow mesenchymal stem cell apoptosis, migration and cytokine
secretion. Protein Cell. 2:845–854. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong J, Meng HB, Hua J, Song ZS, He ZG,
Zhou B and Qian MP: The SDF-1/CXCR4 axis regulates migration of
transplanted bone marrow mesenchymal stem cells towards the
pancreas in rats with acute pancreatitis. Mol Med Rep. 9:1575–1582.
2014.PubMed/NCBI
|
|
17
|
Ghadge SK, Mühlstedt S, Ozcelik C and
Bader M: SDF-1α as a therapeutic stem cell homing factor in
myocardial infarction. Pharmacol Ther. 129:97–108. 2011. View Article : Google Scholar
|
|
18
|
Yu J, Li M, Qu Z, Yan D, Li D and Ruan Q:
SDF-1/CXCR4-mediated migration of transplanted bone marrow stromal
cells toward areas of heart myocardial infarction through
activation of PI3K/Akt. J Cardiovasc Pharmacol. 55:496–505.
2010.PubMed/NCBI
|
|
19
|
Wang Y, Deng Y and Zhou GQ:
SDF-1α/CXCR4-mediated migration of systemically transplanted bone
marrow stromal cells towards ischemic brain lesion in a rat model.
Brain Res. 1195:104–112. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koury MJ and Bondurant MC: Maintenance by
erythropoietin of viability and maturation of murine erythroid
precursor cells. J Cell Physiol. 137:65–74. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rölfing JH, Jensen J, Jensen JN, Greve AS,
Lysdahl H, Chen M, Rejnmark L and Bünger C: A single topical dose
of erythropoietin applied on a collagen carrier enhances calvarial
bone healing in pigs. Acta Orthop. 85:201–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Teixeira M, Rodrigues-Santos P, Garrido P,
Costa E, Parada B, Sereno J, Alves R, Belo L, Teixeira F,
Santos-Silva A and Reis F: Cardiac antiapoptotic and
proproliferative effect of recombinant human erythropoietin in a
moderate stage of chronic renal failure in the rat. J Pharm
Bioallied Sci. 4:76–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weng S, Zhu X, Jin Y, Wang T and Huang H:
Protective effect of erythropoietin on myocardial infarction in
rats by inhibition of caspase-12 expression. Exp Ther Med.
2:833–836. 2011.
|
|
24
|
Chen S, Li J, Peng H, Zhou J and Fang H:
Administration of erythropoietin exerts protective effects against
glucocorticoid-induced osteonecrosis of the femoral head in rats.
Int J Mol Med. 33:840–848. 2014.PubMed/NCBI
|
|
25
|
Xiong M, Chen S, Yu H, Liu Z, Zeng Y and
Li F: Neuroprotection of erythropoietin and methylprednisolone
against spinal cord ischemia-reperfusion injury. J Huazhong Univ
Sci Technolog Med Sci. 31:652–656. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gorio A, Gokmen N, Erbayraktar S, Yilmaz
O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A and
Brines M: Recombinant human erythropoietin counteracts secondary
injury and markedly enhances neurological recovery from
experimental spinal cord trauma. Proc Natl Acad Sci USA.
99:9450–9455. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choi D, Schroer SA, Lu SY, Wang L, Wu X,
Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H, et al: Erythropoietin
protects against diabetes through direct effects on pancreatic beta
cells. J Exp Med. 207:2831–2842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
MacRedmond R, Singhera GK and Dorscheid
DR: Erythropoietin inhibits respiratory epithelial cell apoptosis
in a model of acute lung injury. Eur Respir J. 33:1403–1414. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kakavas S, Demestiha T, Vasileiou P and
Xanthos T: Erythropoetin as a novel agent with pleiotropic effects
against acute lung injury. Eur J Clin Pharmacol. 67:1–9. 2011.
View Article : Google Scholar
|
|
30
|
Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu
J, Phinney DG, LaMarca HL, Florez L, Morris CB, Hoyle GW and
Scandurro AB: Erythropoietin, a hypoxia-regulated factor, elicits a
pro-angiogenic program in human mesenchymal stem cells. Exp
Hematol. 35:640–652. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu NM, Tian J, Wang WW, Han GF, Cheng J,
Huang J and Zhang JY: Effect of erythropoietin on mesenchymal stem
cell differentiation and secretion in vitro in an acute kidney
injury microenvironment. Genet Mol Res. 12:6477–6487. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nair AM, Tsai YT, Shah KM, Shen J, Weng H,
Zhou J, Sun X, Saxena R, Borrelli J Jr and Tang L: The effect of
erythropoietin on autologous stem cell-mediated bone regeneration.
Biomaterials. 34:7364–7371. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kwon BK, Oxland TR and Tetzlaff W: Animal
models used in spinal cord regeneration research. Spine.
27:1504–1510. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng W, Bivalacqua TJ, Chattergoon NN,
Jeter JR Jr and Kadowitz PJ: Engineering ex vivo-expanded marrow
stromal cells to secrete calcitonin gene-related peptide using
adenoviral vector. Stem Cells. 22:1279–1291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bobadilla M, Sainz N, Abizanda G, Orbe J,
Rodriguez JA, Páramo JA, Prósper F and Pérez-Ruiz A: The CXCR4/SDF1
axis improves muscle regeneration through MMP-10 activity. Stem
Cells Dev. 23:1417–1427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Basso DM, Beattie MS and Bresnahan JC: A
sensitive and reliable locomotor rating scale for open field
testing in rats. J Neurotrauma. 12:1–21. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang S, Wu Z, Chiang P, Fink DJ and Mata
M: Vector-mediated expression of erythropoietin improves functional
outcome after cervical spinal cord contusion injury. Gene Ther.
19:907–914. 2012. View Article : Google Scholar :
|
|
38
|
McDonald JW and Sadowsky C: Spinal-cord
injury. Lancet. 359:417–425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Noguchi CT, Wang L, Rogers HM, Teng R and
Jia Y: Survival and proliferative roles of erythropoietin beyond
the erythroid lineage. Expert Rev Mol Med. 10:e362008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Paschos N, Lykissas MG and Beris AE: The
role of erythropoietin as an inhibitor of tissue ischemia. Int J
Biol Sci. 4:161–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Grasso G, Sfacteria A, Passalacqua M,
Morabito A, Buemi M, Macrì B, Brines ML and Tomasello F:
Erythropoietin and erythropoietin receptor expression after
experimental spinal cord injury encourages therapy by exogenous
erythropoietin. Neurosurgery. 56:821–827; discussion 821–827. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qi C, Xu M, Gan J, Yang X, Wu N, Song L,
Yuan W and Liu Z: Erythropoietin improves neurobehavior by reducing
dopaminergic neuron loss in a 6 hydroxydopamine induced rat model.
Int J Mol Med. 34:440–450. 2014.PubMed/NCBI
|
|
43
|
Celik M, Gökmen N, Erbayraktar S,
Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E,
Cerami A and Brines M: Erythropoietin prevents motor neuron
apoptosis and neurologic disability in experimental spinal cord
ischemic injury. Proc Natl Acad Sci USA. 99:2258–2263. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kitaori T, Ito H, Schwarz EM, Tsutsumi R,
Yoshitomi H, Oishi S, Nakano M, Fujii N, Nagasawa T and Nakamura T:
Stromal cell-derived factor 1/CXCR4 signaling is critical for the
recruitment of mesenchymal stem cells to the fracture site during
skeletal repair in a mouse model. Arthritis Rheum. 60:813–823.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stich S, Haag M, Häupl T, Sezer O, Notter
M, Kaps C, Sittinger M and Ringe J: Gene expression profiling of
human mesenchymal stem cells chemotactically induced with CXCL12.
Cell Tissue Res. 336:225–236. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jaerve A, Schira J and Müller HW: Concise
review: the potential of stromal cell-derived factor 1 and its
receptors to promote stem cell functions in spinal cord repair.
Stem Cells Transl Med. 1:732–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu N, Patzak A and Zhang J:
CXCR4-overexpressing bone marrow-derived mesenchymal stem cells
improve repair of acute kidney injury. Am J Physiol Renal Physiol.
305:F1064–F1073. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hu C, Yong X, Li C, Lü M, Liu D, Chen L,
Hu J, Teng M, Zhang D, Fan Y and Liang G: CXCL12/CXCR4 axis
promotes mesenchymal stem cell mobilization to burn wounds and
contributes to wound repair. J Surg Res. 183:427–434. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fan DY, Liu Y, Xu FC, et al: CXCL12/CXCR4
biology axis effects on the repair of spinal cord injury with bone
marrow mesenchymal stem cells. J Clin Rehabil Tissue Eng Res.
15:6651–6656. 2011.
|
|
50
|
Karp JM and Leng Teo GS: Mesenchymal stem
cell homing: the devil is in the details. Cell Stem Cell.
4:206–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ries C, Egea V, Karow M, Kolb H, Jochum M
and Neth P: MMP-2, MT1-MMP, and TIMP-2 are essential for the
invasive capacity of human mesenchymal stem cells: differential
regulation by inflammatory cytokines. Blood. 109:4055–4063. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu Y, Wang L, Kikuiri T, Akiyama K, Chen
C, Xu X, Yang R, Chen W, Wang S and Shi S: Mesenchymal stem
cell-based tissue regeneration is governed by recipient T
lymphocytes via IFN-γ and TNF-α. Nat Med. 17:1594–1601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Villa P, Bigini P, Mennini T, Agnello D,
Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman
TR, et al: Erythropoietin selectively attenuates cytokine
production and inflammation in cerebral ischemia by targeting
neuronal apoptosis. J Exp Med. 198:971–975. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sekiguchi Y, Kikuchi S, Myers RR and
Campana WM: ISSLS prize winner: Erythropoietin inhibits spinal
neuronal apoptosis and pain following nerve root crush. Spine.
28:2577–2584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Arishima Y, Setoguchi T, Yamaura I, Yone K
and Komiya S: Preventive effect of erythropoietin on spinal cord
cell apoptosis following acute traumatic injury in rats. Spine.
31:2432–2438. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Knabe W, Sirén AL, Ehrenreich H and Kuhn
HJ: Expression patterns of erythropoietin and its receptor in the
developing spinal cord and dorsal root ganglia. Anat Embryol
(Berl). 210:209–219. 2005. View Article : Google Scholar
|
